Candel Therapeutics, Inc.

CADL Healthcare Biotechnology

Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00. In the quarter to June 2026, EPS fell 477.8%, free cash flow fell 93.4% and total debt rose 525.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

8.19 0.72 −8.08%
Market cap
$681.8M
P/E
0.0×
Fwd P/E
−1.8×
Dividend yield
—
F-score
1/9
Altman Z
−1.20
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
8.25 13.49 28.05 16.09
Net Debt/EBITDA
6.28 4.66 9.13 5.78
Debt/Equity
0.06 0.91 0.34 0.38
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.19) (0.21) (0.30) (0.23)
Book value per Share
1.46 0.98 2.21 1.70
Free Cash Flow
(10.35) (10.98) (18.71) (17.25)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates